Efficacy and safety of aromatase inhibitors in early breast cancer.

about

Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor.Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer Challenges in clinical patient management.

P2860

Q35095538-D1CD3526-6996-4897-81D6-D220DE44595C Q37356084-84DCB17F-3AE9-4976-994F-F7621760AEBE Q37775020-4F28F897-CF41-4085-BE41-04B1BFB3002A

P2860

Efficacy and safety of aromatase inhibitors in early breast cancer.

Item

http://www.wikidata.org/entity/Q53132333

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Efficacy and safety of aromatase inhibitors in early breast cancer.

@en

Efficacy and safety of aromatase inhibitors in early breast cancer.

@nl

type

Item

label

Efficacy and safety of aromatase inhibitors in early breast cancer.

@en

Efficacy and safety of aromatase inhibitors in early breast cancer.

@nl

prefLabel

Efficacy and safety of aromatase inhibitors in early breast cancer.

@en

Efficacy and safety of aromatase inhibitors in early breast cancer.

@nl

P1476

Efficacy and safety of aromatase inhibitors in early breast cancer.

@en

P2093

Shabana Iqbal

http://www.w3.org/2001/XMLSchema#string

Sundus Ozair

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Cancer statistics, 2005

Estrogen and the risk of breast cancer.

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.

Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition?

P304

547-558

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1517/14740338.7.5.547

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18759707

http://www.w3.org/2001/XMLSchema#string

Efficacy and safety of aromatase inhibitors in early breast cancer.

about

P2860

P2860

Efficacy and safety of aromatase inhibitors in early breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698